Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Orasure Technologies ( (OSUR) ) is now available.
On April 16, 2026, OraSure Technologies announced a cooperation agreement with activist investor Altai Capital, under which Altai withdrew prior director nominations and stockholder proposals and agreed to customary standstill and voting provisions through March 31, 2027. As part of the deal, OraSure appointed healthcare technology executive John D. Bertrand as an independent Class II director, added him to its Nominating and Corporate Governance Committee and committed to include him on its 2026 director slate, while capping board size at eight members before the 2027 annual meeting.
The board also resolved on April 16, 2026 to seek shareholder approval at the 2026 annual meeting to declassify its board structure and phase in annual director elections, a move positioned as strengthening governance, oversight and shareholder engagement. The agreement formalizes a more collaborative relationship with Altai, including regular meetings on financial and strategic matters, signaling a negotiated end to a potential proxy contest and reinforcing OraSure’s broader multi-year transformation and value-creation strategy.
The most recent analyst rating on (OSUR) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Orasure Technologies stock, see the OSUR Stock Forecast page.
Spark’s Take on OSUR Stock
According to Spark, TipRanks’ AI Analyst, OSUR is a Neutral.
The score is held down primarily by weakened financial performance (losses, steep revenue decline, and renewed cash burn). The latest earnings call provides some offset via strong cash/no-debt positioning and credible product/regulatory catalysts, while technicals are neutral and valuation remains challenged due to negative earnings and no dividend support.
To see Spark’s full report on OSUR stock, click here.
More about Orasure Technologies
OraSure Technologies, Inc., listed on Nasdaq as OSUR, is a healthcare diagnostics company specializing in point-of-need and home diagnostic tests and sample management solutions. Through subsidiaries including DNA Genotek, Sherlock Biosciences and BioMedomics, it develops, manufactures and distributes rapid diagnostic tests and sample collection and stabilization devices sold globally to clinical, public health, research, government, pharmaceutical and direct-to-consumer markets.
The company focuses on decentralizing diagnostics to connect people to healthcare wherever they are, aiming to improve access, quality and value of care through effortless testing and sample management innovations. Its products target the discovery and detection of critical medical conditions and are used by clinical laboratories, hospitals, physicians’ offices and community organizations worldwide.
Average Trading Volume: 493,105
Technical Sentiment Signal: Sell
Current Market Cap: $224M
Find detailed analytics on OSUR stock on TipRanks’ Stock Analysis page.